Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Purdue, Houston Methodist to Take Drug Discoveries from the Bench Top to the Bedside

Published: Monday, March 17, 2014
Last Updated: Tuesday, March 18, 2014
Bookmark and Share
The planned collaboration on research and educational initiatives includes clinical trials of drugs developed at Purdue.

Purdue University and Houston Methodist Research Institute plan to collaborate on research and educational initiatives, including clinical trials of drugs developed at Purdue.
The partnership helps to advance the Purdue Moves drug discovery initiative to translate basic research into life-changing treatments.

"Drug discovery is a top priority at Purdue because of our proven strength in this area and because it is an area in which great breakthroughs will truly change the world," said Purdue President Mitch Daniels. "Purdue has a tremendous basic research capability, but we do not have a medical school. We need partners to translate our discoveries into new medicines and new technologies that save and improve lives. It is a great affirmation of the work done at Purdue that one of the preeminent research hospitals in the world has chosen to partner with us."

Daniels met with Mauro Ferrari, the president and CEO of Houston Methodist Research Institute, on Wednesday (March 12) to sign a memorandum of understanding between the two institutions. Philip Low, Purdue's Ralph C. Corley Distinguished Professor of Chemistry and inaugural director of the Purdue Center for Drug Discovery, also attended the meeting.

Houston Methodist is one of the top clinical trial hospitals in the world and has built infrastructure that quickly brings innovations to the clinic, Low said.

"They know exactly how to bring a drug from the bench top to the bedside and, so, with the strengths that we have at Purdue in discovering new drugs, Houston Methodist makes an ideal partner to really complete the entire journey from discovery to delivery," he said.

The collaboration will make Houston Methodist's infrastructure available to Purdue researchers in the same way it would be available to the institute's own faculty, Ferrari said.
Houston Methodist is focused on the delivery of health care and translating discoveries into solutions in the clinic, and looks for the best possible pipelines of discoveries coming from the academic research world, he said.

It takes 17 years, on average, for a discovery to go from its initial publication in a scientific journal to testing in the clinic. In that time, thousands of lives are lost and more than $1 billion is spent in testing and development, Ferrari said.

"It is necessary that we not only identify great, major scientific breakthroughs, but also the most efficient way to bring those breakthroughs to the clinic and hospitals where those breakthroughs are needed," he said. "I'm very confident that this partnership will bring solutions in areas of health care that will affect our patients, patients throughout the country and patients throughout the world."
Purdue is one of only a few universities in the United States with which Houston Methodist has considered such a partnership, he said.

The partnership is flexible and discussions are ongoing about the details of collaborative initiatives. An educational collaboration is important to both institutions, and Purdue graduate students may have the opportunity to work in the laboratories at Houston Methodist to help take the discoveries through to the point of clinical applications.

"The point of the partnership is to have open communication among researchers and clinicians so that they can learn from each other and work toward the common goal of translating discoveries into new treatments and technologies that benefit mankind," Low said. "It is the first such partnership we have entered into, but we will likely establish similar relationships with one or two other institutions whose expertise aligns with ours in different areas of human health."

Drug discovery is among 10 targeted priorities spelled out in Purdue Moves, an initiative designed to broaden the university's global impact and enhance educational opportunities for its students. All of the moves fall into four broad categories: science, technology, engineering and math (STEM) leadership; world-changing research; transformative education; and affordability and accessibility.



Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Technique Yields Drug, Biomedical Test Results in One Minute
Slug flow microextraction makes it possible to quickly detect the presence of drugs or to monitor certain medical conditions using only a single drop of blood or urine.
Tuesday, October 14, 2014
Purdue to Accelerate Drug Discovery, Development
Purdue Center for Drug Discovery adds to Purdue's strengths and the capacity to translate basic research into life-changing treatments.
Monday, September 16, 2013
Yeast Study Yields Potential for New Cholesterol, Anti-Fungal Drugs
While studying a mutant strain of yeast, Purdue University researchers may have found a new target for drugs to combat cholesterol and fungal diseases.
Thursday, February 28, 2013
MolecularHUB Gives Scientific Information on Fast-moving Diseases
A scientific gateway website that will provide molecular and genetic information on infectious and emerging diseases has been released by Purdue University.
Thursday, October 25, 2012
Gene's function May Give New Target for Cancer Drugs
Scientists have determined that a gene long known to be involved in cancer cell formation and chemotherapy resistance is key to proper RNA creation, and could one day lead to new therapies and drug targets.
Thursday, September 13, 2012
Biochip Helps Study Living Cells
The biochip could speed scientific research, which could accelerate drug development for muscle and nerve disorders.
Friday, November 10, 2006
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!